AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02724969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MILK or Text4Baby text message intervention
Description: MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
Study NCT02724969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MILK or Text4Baby text message intervention
Description: MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
Study NCT03216421 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: Quality of Life questionnaires will be completed by each subject.
Study NCT03350373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Single administration of FYU-981 under Fasted and fed conditions in the morning.
Study NCT01476059 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No telephone follow-up
Description: Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
Study NCT01868490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytokine induced killer cells
Description: at least 10\*9 CIK cells, IV on day 0, 14, 28
Study NCT01722305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT01722305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study NCT01722305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies
Study NCT01722305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT03693703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bi-parametric MRI
Description: Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration
Study NCT03693703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: multi-parametric MRI
Description: T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration
Study NCT04531501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva and NPS test
Description: N/A Our study will not impact their path of care as they will be doing an NHS test which will determine their path of care at the NHS
Study NCT02865837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.~Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.~Right after, a scanner is performed with urinary catheter declamping and emptied bladder.~Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.~Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared.
Study NCT04288999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours
Study NCT04288999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours
Study NCT04288999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Description: Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)
Study NCT04288999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure
Description: Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection
Study NCT04288999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procedure
Description: Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection
Study NCT02000193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.~The treatment will continue until disease progression or intolerable AE.
Study NCT04602273 — intervention group
Intervention type: DRUG
Intervention: Azacitidine Injection [Vidaza]
Study NCT04388111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 10mg of Morphine delivered Intraosseously
Study NCT03189186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Same as arm description
Study NCT03189186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation uses liquid argon in metal needles to freeze tumors. Tumor cells are ruptured due to the forming ice crystals and die. Cryoablation is standardly used in tumors less then 4cm in diameter.
Study NCT03189186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Nephrectomy is the surgical excision of either the entire kidney or a small portion of the kidney. Nephrectomy is standardly used to treat renal cell cancer.
Study NCT05200715 — intervention group
Intervention type: OTHER
Intervention: No intervention is foreseen by the protocol.
Description: Patients will be observed for 10 years at least. Demographic, genetic, clinical, clinimetric, laboratory, radiologic and therapeutic data will be collected both retrospectively and prospectively during routine follow-up visits.
Study NCT01414894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid manipulation
Description: Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
Study NCT01414894 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Manipulation
Description: Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
Study NCT01105910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra Lubricant Eye Drops
Description: 1 to 2 drops in each eye 4 times per day for 30 days
Study NCT01105910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensitive Eyes Eye Drops (Bausch & Lomb)
Description: 1 to 2 drops in each eye 4 times per day for 30 days
Study NCT05301985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preoperative nutrition
Description: The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
Study NCT04473209 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal therapy
Description: supra and subgingival debridement
Study NCT00461617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: 10mg tablet, 10mg TID
Study NCT03636659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B Liposome
Description: Manufactured for: Auromedics Pharma LLC, USA
Study NCT03636659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmBisome (Amphotericin B) Liposome
Description: Marketed by: Astellas Pharma US, Inc. USA
Study NCT02823509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation-SR15-68_R84-089)
Study NCT04428398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of urine samples with flow cytometry
Description: Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326
Study NCT02292108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietetic counselling
Study NCT02292108 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: dietetic counselling
Study NCT02292108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis and self-hypnosis
Description: Erickson's hypnosis and self-hypnosis
Study NCT06308822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06308822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06308822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06308822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study NCT06308822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04497649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir once daily
Study NCT04497649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: daclatasuvir once daily
Study NCT02454738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultralow dose chest CT scan
Description: Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
Study NCT01451723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
Study NCT01451723 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT02533414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIRS with UAS
Description: Ureteral access sheath (UAS) will be used during RIRS.
Study NCT02533414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS without UAS
Description: Ureteral access sheath will not be used during RIRS.
Study NCT01153165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
Study NCT01153165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
Study NCT02932137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Patients receive low dose recombinant human Interleukin-2（HrIL-2）
Study NCT03068871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACT
Description: Psycho-educational group
Study NCT03068871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CET
Description: Psycho-educational group
Study NCT00663364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiogel AI Lotion, Physiogel Lotion
Description: Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
Study NCT01480960 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation + whole body vibration training
Description: standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
Study NCT04023526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine SC or IV will be administered at a standard dose of 75 mg/m\^2 on days 1-7 of each cycle.
Study NCT04023526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.
Study NCT00952302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Single intravenous infusion of iron 200 mg
Study NCT00952302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
Study NCT00952302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venesection
Description: Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
Study NCT00952302 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Venesection
Description: Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
Study NCT00952302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Two intravenous infusions, each of 200 mg of iron, separated by one day.
Study NCT00952302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron sucrose
Description: Two intravenous infusions, each of 200 mg of iron, separated by one day.
Study NCT00952302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
Study NCT00952302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
Study NCT02986217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular structured assessment of surgical performance
Study NCT01235091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
Description: At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
Study NCT01235091 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
Description: At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
Study NCT01235091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Intervention plus Well-Woman Exam
Description: At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to additionally receive a well-woman examination within seven days.
Study NCT01235091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention
Description: At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
Study NCT01668459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
Study NCT01668459 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Description: Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
Study NCT01893801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
Study NCT01893801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
Study NCT01893801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
Study NCT03147846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: delay of cord clamping for 60 seconds
Study NCT03147846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cord milking
Description: active cord milking 5 times
Study NCT01045486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATP mixed probiotics
Description: - Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
Study NCT01045486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: - Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
Study NCT01909440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Receive whole body RT
Study NCT01909440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional supplementation
Description: Given whey protein supplementation PO
Study NCT01909440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01909440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01909440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01909440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01909440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01909440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies